GHK-Cu: Evidence, Mechanism, Dosing & Legal Status

GHK-Cu (copper tripeptide-1, glycyl-L-histidyl-L-lysine bound to copper) is a naturally occurring copper(II)-tripeptide present in human plasma, saliva and urine. Plasma levels fall roughly 60 percent between ages 20 and 60, which the discovering laboratory links to declining regenerative capacity.1 It is marketed for skin anti-aging, wound healing and hair growth — and, increasingly, as an injectable for systemic regeneration. This monograph separates the well-evidenced topical uses from the speculative injectable ones.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Injectable GHK-Cu is not an FDA-approved drug. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. People with Wilson's disease or other copper-handling disorders must not use copper peptides. Consult a licensed clinician before any health decision.

What is GHK-Cu and how does it work?

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. The GHK sequence resides natively within the alpha-2(I) chain of type I collagen and is released by proteolysis at sites of tissue injury, where it behaves as a matrikine signal.2 It binds copper with a stability constant marginally higher than serum albumin's, so it can acquire copper from albumin and ferry it into cells; critically, the copper's redox activity is silenced while bound, allowing delivery of non-toxic copper.1 The injectable pharmaceutical salt is prezatide copper acetate.

Copper is an obligatory cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin into a stable, organized extracellular matrix. GHK-Cu supplies this copper while also signaling fibroblasts directly. The result is a biphasic remodeling program: at low (1-10 nM) concentrations it stimulates both synthesis and controlled breakdown of collagen and glycosaminoglycans, and modulates matrix metalloproteinases (MMP-2 and MMP-9) and their TIMP inhibitors toward balanced remodeling rather than fibrosis.12 Microarray work reported that GHK altered expression by at least 50 percent in roughly 31 percent of human genes examined, with strong suppression of pro-inflammatory and pro-fibrotic genes — but these are striking in-vitro signatures from largely a single research group and are mechanistic, not outcome, data.3 GHK is an endogenous small peptide cleared rapidly, with no published human pharmacokinetics for the injectable route.3

What is the evidence by indication?

The single most important fact about GHK-Cu is that its evidence quality changes dramatically by route. The strongest controlled human data are topical; the injectable claims are preclinical-to-anecdotal.

The strongest controlled human evidence is the diabetic-ulcer trial. Mulder and colleagues (1994) ran a multicenter, randomized, evaluator-blinded, placebo-controlled trial of GHK-Cu gel on a standardized debridement and offloading protocol; median plantar-ulcer closure was 98.5 percent versus 60.8 percent for vehicle, closure was about three times faster, and infection rates were 7 percent versus 34 percent — though it is a single, dated trial that never advanced to FDA approval, and a separate small study in venous stasis ulcers did not beat placebo.414 You can read the trial abstract directly on PubMed. On the cosmetic side, multiple 12-week studies report increased skin density and reduced wrinkle depth, and the one randomized design — Badenhorst (2016), a nano-lipid-carrier formulation — reduced wrinkle volume by about 56 percent and depth by about 33 percent.2 An important correction to common marketing: the frequently-cited Watson 2009 RCT tested the No7 Protect & Perfect serum, not GHK-Cu, and should not be credited as GHK-Cu evidence.5

Hair growth and post-laser repair are plausible and mechanistically supported — copper inhibits type-1 5-alpha-reductase and GHK-Cu raises VEGF and HGF — but rest on small or preclinical data.67 The dramatic injectable claims (resetting a third of the genome, anti-cancer apoptosis in cell lines, sarcoma suppression in mice) are in-vitro and animal findings, predominantly single-lab, with no controlled human trial supporting injected GHK-Cu for systemic anti-aging, longevity, joint repair or cancer.3

What doses appear in the literature?

Reported strictly as information, not a protocol. For the well-evidenced topical route, copper-tripeptide-1 appears in creams and serums at roughly 0.05 to 2 percent, applied once or twice daily, with cosmetic concentrations characterized as non-irritating in controlled studies.1 In wound gels, dose-finding work in diabetic ulcers compared 0.03, 0.3 and 3 percent, with 0.3 percent optimal — more was not better.414 For the injectable route there is no controlled human dosing data at all: anecdotal subcutaneous protocols cited in clinic and vendor material run around 1 to 2 mg per day in short cycles, and one safety analysis estimated only about 6 to 15 micrograms of elemental copper per dose, far below the tolerable upper intake limit.12 Those injectable figures are anecdotal, not trial-derived, and reconstitution and sterility are compounding-pharmacy-dependent — treat all injectable dosing as unvalidated.

How safe is GHK-Cu?

Topical GHK-Cu at cosmetic concentrations (about 0.05 to 2 percent) is well tolerated, with only mild, transient irritation in a minority and no serious adverse events reported in controlled cosmetic studies.1 Reported issues include contact irritation on a damaged skin barrier, rare copper contact allergy (a patch test is advisable), a metallic taste with oral or spray formats, and anecdotal injection-site redness or flushing.13 The dominant theoretical risk is copper accumulation with chronic high systemic dosing, which can cause abdominal pain, nausea and hepatic injury, making periodic copper and ceruloplasmin monitoring reasonable for any long-term injectable use.12 Because GHK-Cu can stimulate angiogenesis and broadly remodels gene expression, there is a theoretical oncologic caution about applying it over undiagnosed lesions or in active malignancy.3

The contraindications are clearer than the dosing. Wilson's disease — an autosomal-recessive ATP7B copper-handling defect — is an absolute contraindication, because any exogenous copper can worsen hepatic and neurologic accumulation. Other copper-overload or advanced liver disease, known copper allergy, and concurrent copper-chelation therapy (penicillamine, trientine, zinc acetate) are also reasons to avoid it; copper peptides directly oppose those chelating therapies.12 No controlled human data exist for pregnancy or lactation, and because copper crosses the placenta, systemic GHK-Cu should be avoided in those states.13

What is the FDA and WADA status in 2026?

There is no FDA-approved GHK-Cu drug for any indication. It is widely sold as a cosmetic ingredient (Copper Tripeptide-1) in OTC topicals, which are not FDA pre-approved.9 The injectable timeline is more restrictive: in September 2023 the FDA placed a slate of peptides — including injectable GHK-Cu — into 503A Category 2, effectively barring compounding, while noting these were never in Category 1.8 In April 2026 the FDA published a Federal Register notice (April 16, 2026) and updated its categories so the peptides under reconsideration, GHK-Cu among them, would be removed from Category 2 within about seven days (around April 23, 2026).8 A Pharmacy Compounding Advisory Committee review is scheduled before the end of February 2027.8 The critical legal point: removal from Category 2 and PCAC review are not FDA approval — injectable GHK-Cu remains an unapproved drug substance. A 'split path' framing placing non-injectable GHK-Cu in Category 1 appears in secondary sources but is not yet primary-confirmed.1011

For athletes, GHK-Cu and Copper Tripeptide-1 are not named on the WADA Prohibited List as verified to 2026.15 Topical cosmetic use is a non-issue. Injectable or systemic use sits in a grey zone, however, given WADA's catch-all categories and the principle that non-approved-for-human-use substances may be prohibited — athletes should verify via GlobalDRO and their federation before any systemic use.15

Bottom line. GHK-Cu is genuinely one of the better-substantiated cosmetic peptides — but only for its evidenced route. Topically, it has a real, repeated human signal for skin density, wrinkle reduction and diabetic-ulcer healing (Grade B). Hair-growth and post-laser uses are plausible but rest on small or preclinical data (Grade C). Everything injectable and systemic is speculative: no controlled human efficacy data, not FDA-approved, only just removed from Category-2 compounding restriction in April 2026 and still awaiting PCAC review before February 2027. From a root-cause lens, the most defensible use is topical, for skin-barrier and collagen support and wound repair in suitable patients, with copper-handling disorders rigorously excluded. Regulatory facts here are current as of June 2026 and should be re-verified after the February 2027 PCAC review.